Clinical trial · Observational
Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women
Natural History of Human Papillomavirus From Infection to Neoplasia in Adolescents and Young Women - Effect of Tobacco on Cervical Neoplasia in Young Women
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The natural history of human papillomavirus (HPV) is most likely influenced by both innate and adaptive mucosal immunity. More specifically, we hypothesize that Toll like receptors (TLR) play an important role in cervical innate immunity to HPV through secretions of proinflammatory, chemotactic and anti-viral cytokines. Up-regulated TLR expression will also result in activation of dendritic cells and T cells that in turn will promote a T helper (Th) l like response through secretion of several cytokines and consequently, the induction of a successful cell mediated immune (CMI) response.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CIN 2 | Cervical Squamous Intraepithelial Neoplasia 2 | ALIAS | 0.90 |
| CIN 3 | Cervical Squamous Intraepithelial Neoplasia 3 | ALIAS | 0.90 |
| Human Papillomavirus | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- HPV Cohort
- description
- Sexually active young women aged 12 to 22 years of age without a previous history of CIN. Women are not eligible for entry if pregnant or known immunosuppression.
Primary outcomes (1)
- measure
- Cervical Intraepithelial neoplasia (CIN) 2/3
- timeFrame
- 1990 to current
- description
- Observational study of women with HPV
Secondary outcomes (1)
- measure
- HPV persistence
- timeFrame
- 1990 to present
- description
- observational study of women with HPV
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 13 Years
- Maximum age
- 22 Years
Show eligibility criteria text
Inclusion: * Age 12 to 22 years * Sexually active less than 6 years * Received one dose of the HPV vaccine Exclusion: * Planning on moving in 3 years * Prior history of treatment for CIN * Immunocompromised (ie transplant patient, HIV) * Pregnant
References
Publications (0)
Data not yet available